RedPath Integrated Pathology is committed to the early and definitive diagnosis of cancer.  We serve pathologists, clinicians and patients by resolving diagnostic dilemmas.  Diagnostic dilemmas occur in the context of incomplete information obtained from biopsy specimens using traditional pathology techniques and when cancers do not respond to treatments as predicted.   

RedPath's scientists recognized early in the evolution of genetic sciences that genetic mutations always precede the onset of cancer.  Through study and experimentation they developed patented techniques to extract objective and quantitative genetic information from the most minute tissue biopsy, cytology and fluid specimens.  By integrating traditional pathology analysis with genetic mutational analysis they developed PathFinderTG®, a diagnostic platform that resolves diagnostic dilemmas.

Diagnostic dilemmas are increasing as advances in imaging and endoscopic sampling technologies capture smaller and smaller specimens for diagnostic testing.  PathFinderTG, however, produces accurate results from these specimens and allows RedPath to lead the way to early and definitive cancer diagnosis. 

Without the clear, accurate and definitive molecular-based information that PathFinderTG provides, patients may cycle through second opinions, testing and retesting, and delayed treatment—even undergoing unnecessary or inappropriate treatment.  PathFinderTG provides physicians and patients with an accurate and objective diagnosis, offering strong support for the right treatment plan.